Table 1 Stromal and epithelial periostin expression in prostate cancer and clinico-pathological parameters of the training cohort
From: Periostin is up-regulated in high grade and high stage prostate cancer
| Â | Total n (%) | Periostin stromal low n (%) | Periostin stromal high n (%) | Periostin epithelial low n (%) | Periostin epithelial high n (%) | p-values stromal/epithelial |
|---|---|---|---|---|---|---|
All cases | 93(100) | 45 (48.4) | 48 (51.6) | 87 (93.5) | 6 (6.5) | Â |
Age | Â | Â | Â | Â | Â | 0.905/ 0.484 |
≤ 64 | 49 (52.7) | 24 (49.0) | 25 (51.0) | 45 (91.8) | 4 (8.2) |  |
>64 | 44 (47.3) | 21 (47.7) | 23 (52.3) | 42 (95.5) | 2 (4.5) | Â |
pT-status | Â | Â | Â | Â | Â | 0.573/0.026 |
pT2 | 42 (45.2) | 22 (52.4) | 20 (47.6) | 42 (100) | 0 (0) | Â |
pT3/4 | 51 (54.8) | 23 (45.1) | 28 (54.9) | 43 (84.3) | 6 (11.7) | Â |
Gleason score | Â | Â | Â | Â | Â | 0.523/ 0.404 |
3-6 | 23 (24.8) | 13 (56.5) | 10 (43.5) | 22 (95.7) | 1 (4.3) | Â |
7 | 39 (41.9) | 19 (48.7) | 20 (51.3) | 38 (97.4) | 1 (2.6) | Â |
8-10 | 31 (33.3) | 13 (41.9) | 18 (58.1) | 27 (87.1) | 4 (12.9) | Â |
Residual tumour a | Â | Â | Â | Â | Â | 0.322/ 0.052 |
R0 | 50 (54.9) | 26 (52.0) | 24 (48.0) | 49 (98.0) | 1 (0.02) | Â |
R1 | 41 (45.1) | 17(41.5) | 24 (58.5) | 36 (87.8) | 5 (12.2) | Â |